This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Previewing Tetraphase Oral Antibiotic Study Results

NEW YORK (TheStreet) -- Tetraphase (TTPH - Get Report) is getting ready to report data from the lead-in stage of a phase III study of eravacycline in which the experimental antibiotic is first given by intravenous infusion and then transitioned to an oral form. The study enrolls patients with complicated urinary tract infections (cUTI). Tetraphase has told investors to expect results in September.

The most significant issue surrounding the study, known as IGNITE 2, is that the oral formulation of eravacycline has a relatively low bioavailability (at most 30% but more likely in the 20% to 25% range) compared to other oral antibiotics that range from 50% to 90% plus. This means the oral dose requires more drug to generate the serum concentrations needed to produce the desired effect. The unabsorbed drug also sits in the gastrointestinal tract with the potential to affect the natural bacterial flora of the gut and create tolerability issues.

Tetraphase designed the lead-in stage of the IGNITE 2 study for two primary reasons: 1) Determine if a low or high dose of eravacycline offers the best efficacy/side effect profile; and 2) Provide safety and tolerability data to make a decision about further developing eravacycline as an oral antibiotic. If an oral dose of eravacycline doesn't work or isn't adequately tolerated, Tetraphase will just continue developing an intravenous formulation of the antibiotic.

While it is unclear what the data would need to look like to axe the trial, I suspect it will depend on the rate of patient drop outs. In other words, you would expect GI discomfort to be an issue, but are the patients able to soldier on to complete the treatments? Too many patients dropping out of the study will lower the intent-to-treat efficacy because they will count as failures. Tetraphase can still analyze the study for efficacy on a per-protocol basis using patients who completed treatment. A less likely but more significant red flag would be the development of c. difficile infections.

I do not think there is an overwhelmingly clear view of how the eravacycline trial will read out but I would lean towards the oral formulation showing GI tolerability issues but not enough for the company to end the trial. At its current valuation, I would also add that the market is taking the potential risks seriously, so the risk/reward may be skewed for the bullish view. That being said, bad data would certainly send Tetraphase's stock price lower.

As I have noted before, eravacycline still has a decent commercial prospect as an intravenous-only antibiotic so a sell off on bad data from the intravenous-to-poral study could provide a compelling long-term entry point. If the data are positive, however, then this de-risks the oral formulation greatly and increases the commercial potential. 

Sobek has no position in Tetraphase.

David Sobek has been writing on biotech for a number of years through various outlets with a general focus on small cap oncology and antibiotics companies. He received his PhD in political science from Pennsylvania State University in 2003 and a BA in international relations from The College of William and Mary in 1997.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
TTPH $10.99 -1.60%
AAPL $118.82 0.91%
FB $105.75 -1.10%
GOOG $748.29 -1.00%
TSLA $218.20 0.21%


Chart of I:DJI
DOW 17,812.19 +19.51 0.11%
S&P 500 2,089.14 +2.55 0.12%
NASDAQ 5,102.8080 +0.33 0.01%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs